1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026

  • July 2017
  • 47 pages
  • GlobalData
Report ID: 3389019

Summary

Table of Contents

Search Inside

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026

Summary
Acute Myeloid Leukemia (AML), also known as myelogenous leukemia, acute myelocytic leukemia, or acute nonlymphocytic leukemia, is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women (ACS, 2013; O’Donnell et al., 2012). AML starts in the bone marrow, where the developing white blood cells-including granulocytes and monocytes-mature abnormally, grow uncontrollably, and quickly overcrowd the blood, spreading into other parts of the body, including the lymph nodes, liver, and brain (ACS, 2013; ASCO, 2012). The symptoms are nonspecific and may include weight loss, fatigue, fever, problems with bleeding and clotting, and swelling of the liver and spleen (ACS, 2013).

In 2016, the 7MM had 43,592 diagnosed incident cases of AML. This is expected to increase to 52,526 diagnosed incident cases of AML by 2026, at an Annual Growth Rate (AGR) of 2.05%. The increase is driven by the aging population in the 7MM.

In 2016, the 7MM had 57,581 five-year diagnosed prevalent cases of AML. This is expected to increase to 66,743 by 2026, at an AGR of 1.54%. The US had the highest number of diagnosed incident and five-year prevalent cases of AML. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

Our epidemiologists provide a detailed segmentation of the diagnosed incident and five-year diagnosed prevalent cases of AML by subtypes and risk group classification, which are both important factors for predicting the prognosis in patients as well as specific treatment modalities for AML.

The report "EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026", provides an overview of the risk factors and the global and historical epidemiological trends for AML in the seven major markets (7MM): US, France, Germany, Italy, Spain, UK, and Japan.

In addition, this report also includes a 10-year epidemiological forecast for the following segmentations in adults ages 18 years and older across the 7MM -
- Diagnosed incident cases of AML (adjusted for coding differences between cancer registries), segmented by ages 18-59 years and ages 60 years and older
- Five-year diagnosed prevalent cases of AML, segmented by ages 18-59 years and ages 60 years and older
- Diagnosed incident cases of APL and secondary AML, segmented by ages 18-59 years and ages 60 years and older
- Diagnosed incident cases of AML with mutations (FLT3-ITD [internal tandem duplications], FLT3-TKD [tyrosine kinase domain], IDH [isocitrate dehydrogenase] 1 and IDH2), core binding factor (CBF) AML with KIT mutation, and biomarker CD33+
- Diagnosed incident cases of AML classified into favorable-, intermediate-, and adverse-risk groups.

Scope
- The Acute Myeloid Leukemia (AML) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of AML in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of AML, segmented by ages 18-59 years and ages 60 years and older; five-year diagnosed prevalent cases of AML, segmented by ages 18-59 years and ages 60 years and older; diagnosed incident cases of (acute promyelocytic leukemia) APL and secondary AML, segmented by ages 18-59 years and ages 60 years and older; diagnosed incident cases of AML with mutations (FLT3-ITD [internal tandem duplications], FLT3-TKD [tyrosine kinase domain], IDH [isocitrate dehydrogenase] 1 and IDH2), core binding factor (CBF) AML with KIT mutation, and biomarker CD33+; and diagnosed incident cases of AML classified into favorable-, intermediate-, and adverse-risk groups.
- The AML epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The AML EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global AML market.
- Quantify patient populations in the global AML market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AML therapeutics in each of the markets covered.
- Identify the percentage of AML diagnosed incident and five-year diagnosed prevalent cases by various clinical segmentations.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Acute Myeloid Leukemia – Opportunity Analysis and Forecasts to 2026

  • $ 10995
  • Industry report
  • October 2017
  • by GlobalData

Acute myeloid leukemia (AML) is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. Although a number of acquired genetic and ...

Global Leukemia Therapeutics Market Analysis & Trends - Industry Forecast to 2025

  • $ 4200
  • Industry report
  • July 2017
  • by Accuray Research LLP

The Global Leukemia Therapeutics Market is poised to grow at a CAGR of around 17.5% over the next decade to reach approximately $2.6 billion by 2025. Some of the prominent trends that the market is witnessing ...

Leukemia Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

  • $ 4000
  • Industry report
  • June 2017
  • by GlobalData

Leukemia Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, “Leukemia Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides ...


Download Unlimited Documents from Trusted Public Sources

Gene Therapy Forecast in the US

  • September 2017
    2 pages
  • Gene Therapy  

    Leukemia  

  • United States  

    North America  

View report >

Cancer Statistics in the Netherlands

  • September 2017
    7 pages
  • Cancer  

    Cancer  

  • Netherlands  

View report >

Cancer Statistics and Sexually Transmitted Disease Statistics in the US

  • September 2017
    15 pages
  • Cancer  

    Sexually Transm...  

  • United States  

View report >

Cancer Statistics

17 days ago

Related Market Segments :

Leukemia
Cancer

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.